Inari Medical, Inc. (NASDAQ:NARI) Director Sells $58,040.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 1,451 shares of the stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total value of $58,040.00. Following the sale, the director now directly owns 999,782 shares in the company, valued at approximately $39,991,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

William Hoffman also recently made the following trade(s):

• On Monday, March 18th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $41.13, for a total value of $1,645,200.00.

Inari Medical Price Performance

NASDAQ NARI opened at $38.64 on Friday. Inari Medical, Inc. has a twelve month low of $37.92 and a twelve month high of $71.85. The business’s fifty day moving average is $47.29 and its 200 day moving average is $55.52.

Inari Medical (NASDAQ:NARI) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The firm had revenue of $132.10 million for the quarter, compared to analyst estimates of $131.82 million. During the same period last year, the business earned ($0.11) EPS. The company’s revenue was up 22.5% compared to the same quarter last year. Equities research analysts forecast that Inari Medical, Inc. will post -0.39 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently issued reports on NARI. Truist Financial reduced their price target on Inari Medical from $61.00 to $52.00 and set a “hold” rating on the stock in a research report on Friday, March 22nd. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $75.00 target price on shares of Inari Medical in a report on Friday, April 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 target price on shares of Inari Medical in a report on Wednesday, March 6th. Finally, Piper Sandler downgraded Inari Medical from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $85.00 to $55.00 in a report on Thursday, February 29th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $73.71.

Institutional Investors Weigh In On Inari Medical

Several hedge funds have recently modified their holdings of NARI. Parkside Financial Bank & Trust acquired a new stake in shares of Inari Medical during the 1st quarter valued at $25,000. Quarry LP acquired a new stake in shares of Inari Medical during the 2nd quarter valued at $27,000. Fifth Third Bancorp boosted its holdings in shares of Inari Medical by 54.3% during the 3rd quarter. Fifth Third Bancorp now owns 486 shares of the company’s stock valued at $32,000 after acquiring an additional 171 shares in the last quarter. Point72 Middle East FZE acquired a new stake in shares of Inari Medical during the 4th quarter valued at $55,000. Finally, FMR LLC boosted its holdings in shares of Inari Medical by 42.6% during the 2nd quarter. FMR LLC now owns 824 shares of the company’s stock valued at $56,000 after acquiring an additional 246 shares in the last quarter. Institutional investors and hedge funds own 90.98% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.